About NeoNavia AB
NeoNavia AB is a Swedish medical technology company dedicated to advancing the diagnostics and treatment of cancer. The company has created an innovative biopsy system called NeoNavia®. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The innovative pulse biopsy system is designed to offer clinicians and patients reliable tissue sampling with high tissue yield for correct diagnosis and individualized treatment. NeoNavia is commercially available in Germany, Switzerland, and the US.
Growing market for breast biopsies
Annually, at least 6 million breast biopsies are performed to diagnose suspected cancer. Every year, about 2.1 million women globally are diagnosed with breast cancer, and this number is increasing by at least 5% yearly, with an 8.6% compound annual growth rate from 2021 to 2025. The global market for breast cancer diagnosis is estimated at $1.7 billion annually, with 50% of this market in the USA.
As the share of non-surgical biopsies increases, the share of surgical biopsies decreases. More tumors are detected earlier thanks to extended screening programs and new screening techniques. New treatments have increased the need for biopsies for both diagnosis and monitoring effectiveness.
NeoNavia – a unique biopsy system
NeoNavia is the registered trademark for the entire biopsy system intended for ultrasound-guided tissue sampling. NeoNavia consists of a base unit, a hand-held driver, and three types of biopsy needles. All three needle types are driven by pulses that facilitate needle insertion and precise placement of the needle in the suspected tumor. The system is designed to offer clinicians and patients precise and reliable tissue sampling for correct diagnosis and individualized treatment.
A new innovative technology
The patented pulse technology is based on a pneumatic needle insertion mechanism creating a high needle acceleration and velocity. In combination with a short stroke length, in the order of millimeters, and the ability to apply multiple consecutive pulses, the physician is able to deploy the biopsy needle into tissue in a stepwise and controlled manner without noticeable deformation or displacement of surrounding tissue on the ultrasound image and irrespective of tissue properties. The technology thus ensures precise access and flexibility for tissue sampling even in challenging lesion locations and in dense breast tissue.
Patent protection
Technologies are protected in five strong patent families across larger European countries, China, and the USA.
The future of breast cancer biopsy
It is our vision that NeoNavia's pulse technology becomes the new standard for all ultrasound-guided breast cancer biopsies, improving both precision and reliability, contributing to correct diagnoses, and enabling individualized treatment without delays for every individual breast cancer patient.
